Key points are not available for this paper at this time.
The cost to develop a cancer drug is 648. 0 million, a figure significantly lower than prior estimates. The revenue since approval is substantial (median, 1658. 4 million; range, 204. 1 million to 22 275. 0 million). This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.
Prasad et al. (Mon,) studied this question.